Back

SCN5A H558R polymorphism reduces the risk of flecainide-related toxicity and inefficacy

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation recurrence: clinical, genetic, and biomarker predictors Rhythm Control, Antiarrhythmic Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Mauro Trincado Ave

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

5 More presentations in this session

Presentation thumbnail
Peak atrial longitudinal strain in predicting recurrence of atrial fibrillation after cardioversion
Doctor A. Garner (Slagelse, DK)
Abstract
Presentation thumbnail
Predictors of long-term atrial fibrillation recurrence following catheter ablation: a UK multicenter study
Doctor N. Chandan (Coventry, GB)
Abstract
Presentation thumbnail
Baseline multidomain atrial vulnerability stratifies recurrence after AF ablation in elderly patients
Professor D. Malidze (Tbilisi, GE)
Abstract
Presentation thumbnail
Plasma level of extracellular matrix biomarkers is associated with the recurrence of atrial fibrillation
Mr S. Andrup (Oslo, NO)
Abstract
Presentation thumbnail
REVERSE-AF Score: development of a clinical tool to predict atrial fibrillation recurrence after electrical cardioversion
Doctor M. Santos Silva (Aveiro, PT)
Abstract

Access the full session

Session thumbnail
Atrial fibrillation recurrence: clinical, genetic, and biomarker predictors

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.
1 September 2024
thumbnail
Congress Presentation
Dilated cardiomyopathy in SCN5A variant carriers
14 April 2026
thumbnail
Congress Presentation
Flecainide vs Amiodarone for the cardioversion of Atrial Fibrillation in the Emergency Department in patients with Coronary Artery Disease and preserved ejection fraction. FLECA-ED study
1 April 2025
thumbnail
Congress Presentation
Mexiletine rescues the mixed phenotype in SCN5A-1795insD hiPSC-CMs
23 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources